Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 3/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186147 | 0.90 | NPC1 (0.54) | CCR3CA12CA1CA2MMP2 | |
| SCHEMBL10185122 | 0.89 | CA12 (0.56) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL10185047 | 0.88 | NPC1 (0.55) | DGAT1GAA | |
| SCHEMBL10184966 | 0.86 | ACHE (0.52) | CCR3DGAT1 | |
| SCHEMBL10185255 | 0.86 | NPC1 (0.47) | CCR3CA12CA1CA2MMP2 | |
| SCHEMBL10185270 | 0.85 | MMP13 (0.57) | MMP13CA12CA1CA2MMP2 | |
| SCHEMBL10186477 | 0.84 | ACHE (0.50) | CCR3DGAT1 | |
| SCHEMBL10184403 | 0.84 | DGAT1 (0.54) | DGAT1EPHX2 | |
| SCHEMBL10185254 | 0.84 | MAPK14 (0.50) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL10185608 | 0.84 | SMN1; SMN2 (0.57) | TRPV1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | MTNR1B 592/4885MTNR1A 691/4885TRPV1 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.